Roivant reports positive Phase 3 Lisraya trials in non-infectious uveitis
Roivant and its spinout Priovant reported on Wednesday that Lisraya, an immune-modifying pill, was more effective than placebo in treating non-infectious uveitis in two Phase 3 trials involving 371 patients. The results could open a new market for the drug,…
